short term prednisolon in itp
Phase 3
Completed
- Conditions
- Treatment Patients with acute immune thrombocytopenia.Immune thrombocytopenic purpuraD69.3
- Registration Number
- IRCT20230718058831N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
childeren with acuteImmune Thrombocytopenia
Exclusion Criteria
Patients with active infections and septicemia
patients with positive antinuclear antibody
patients with Evans syndrome
Patients with chronic immune thrombocytopenia
Patients with positive glue culture
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet count of patients after a short course of prednisolone. Timepoint: Comment on the number of blood platelets at different time points before the start and days 2, 7, 30 and 60 after the start of the treatment period. Method of measurement: Compelete blood count.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie prednisolone's efficacy in acute immune thrombocytopenia (ITP) as studied in IRCT20230718058831N1?
How does short-term oral prednisolone compare to standard-of-care treatments like IVIG or TPO-RAs in newly diagnosed ITP patients?
Which biomarkers correlate with response to short-term corticosteroid therapy in immune thrombocytopenic purpura (D69.3) trials?
What adverse events are associated with 2-week prednisolone regimens in ITP management and how are they mitigated?
Are there combination therapies or alternative drugs to prednisolone for acute ITP treatment in phase III clinical trials?